XAGRID

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Germany, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug XAGRID contains one active pharmaceutical ingredient (API):

1	Anagrelide UNII VNS4435G39 - ANAGRELIDE HYDROCHLORIDE ANHYDROUS
	Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III and suppress expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.
	Read more about Anagrelide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XAGRID Capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX35	Anagrelide	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX35

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	04164572, 06909958, 14293388, 14336873, 14399052, 15193387, 15609209
EE	Ravimiamet	1208359
ES	Centro de información online de medicamentos de la AEMPS	04295001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	021999
FR	Base de données publique des médicaments	64599534
GB	Medicines & Healthcare Products Regulatory Agency	369083, 375384, 381761, 90406
IE	Health Products Regulatory Authority	88375
IT	Agenzia del Farmaco	036745014
LT	Valstybinė vaistų kontrolės tarnyba	1031388
NL	Z-Index G-Standaard, PRK	77526
PL	Rejestru Produktów Leczniczych	100313581
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68329001